Drugs / Chondrogen
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00702741 | Jun 2008 → Sep 2011 | — | Mesoblast, Ltd. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04520945 Comparator | Oct 2020 → Sep 2021 | osteoarthritis, knee | Meluha Life Sciences SDN BHD | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Chondrogen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00702741 ↗ |
| Modality | Cell therapy | “human mesenchymal stem cells (hMSCs) (Chondrogen)” NCT00702741 ↗ |
| Route | Other | “single intra-articular injection” NCT00702741 ↗ |